Recommended Dosing Intervals for Muscle Relaxants in Acute Muscle Spasms
For acute muscle spasms, cyclobenzaprine (Flexeril) should be taken every 8 hours (three times daily) and tizanidine (Zanaflex) should be taken every 6-8 hours, with a maximum of three doses in 24 hours.
Cyclobenzaprine (Flexeril) Dosing
- Initial dosing: 5-10 mg three times daily 1
- Maximum duration: Short-term use only (2-3 weeks) as effectiveness for longer periods is not established 1
- Maximum daily dose: 30 mg per day
- Timing considerations: Should be used as an adjunct to rest and physical therapy 1
Tizanidine (Zanaflex) Dosing
- Initial dosing: Start with 4 mg per dose 2
- Dosing interval: Every 6-8 hours as needed 2
- Maximum frequency: No more than 3 doses in 24 hours 2
- Maximum daily dose: Should not exceed 36 mg total daily 2
- Timing considerations: Effect peaks at 1-2 hours and dissipates between 3-6 hours 2
Important Clinical Considerations
Drug Selection Factors
- Both medications are effective for acute muscle spasms, but selection should be based on:
- Patient comorbidities
- Potential drug interactions
- Side effect profiles
Monitoring and Precautions
Cyclobenzaprine:
- Contraindicated with MAO inhibitors or within 14 days of discontinuing MAOIs
- Avoid in patients with cardiac conditions (heart block, arrhythmias)
- Monitor for sedation, dry mouth, and dizziness 3
Tizanidine:
Special Populations
Elderly patients:
Patients with liver/kidney disease:
- Muscle relaxants are contraindicated in significant liver and kidney disease 3
Administration Guidelines
- Cyclobenzaprine: Can be taken without regard to meals
- Tizanidine: Be consistent with taking either with or without food due to significant food effects on absorption 2
- Both medications: Advise patients to avoid activities requiring mental alertness until response to medication is known 3
Remember that muscle relaxants should only be used for short periods as they are generally indicated for acute conditions of limited duration, and long-term efficacy data is lacking.